Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
- PMID: 10888034
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
Abstract
Angiogenesis, or the sprouting of new blood vessels, is a central process in the growth of solid tumors. For many cancers, the extent of vascularization of a tumor is a negative prognostic indicator signifying aggressive disease and increased potential for metastasis. Recent efforts to understand the molecular basis of tumor-associated angiogenesis have identified several potential therapeutic targets, including the receptor tyrosine kinases for the angiogenic factor vascular endothelial growth factor (VEGF). Here we review the approach taken at SUGEN, Inc. to discover and develop small molecule inhibitors of receptor tyrosine kinases as anti-angiogenic agents. We focus on SU5416, a selective inhibitor of VEGF receptors that is currently in clinical development for the treatment of advanced malignancies. Its biochemical, biological and pharmacological properties are reviewed and clinical implications discussed.
Similar articles
-
Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.Microvasc Res. 2002 May;63(3):304-15. doi: 10.1006/mvre.2001.2383. Microvasc Res. 2002. PMID: 11969307
-
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.Clin Cancer Res. 2000 Dec;6(12):4848-58. Clin Cancer Res. 2000. PMID: 11156244
-
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.Cancer Res. 1999 Jan 1;59(1):99-106. Cancer Res. 1999. PMID: 9892193
-
Angiogenesis inhibition in solid tumors.Cancer J. 2001 Nov-Dec;7 Suppl 3:S120-8. Cancer J. 2001. PMID: 11779082 Review.
-
Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases.Curr Opin Chem Biol. 2004 Aug;8(4):432-41. doi: 10.1016/j.cbpa.2004.06.009. Curr Opin Chem Biol. 2004. PMID: 15288254 Review.
Cited by
-
SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation.PLoS One. 2012;7(9):e44547. doi: 10.1371/journal.pone.0044547. Epub 2012 Sep 6. PLoS One. 2012. PMID: 22970246 Free PMC article.
-
Lack of VEGFR2 signaling causes maldevelopment of the intestinal microvasculature and facilitates necrotizing enterocolitis in neonatal mice.Am J Physiol Gastrointest Liver Physiol. 2016 May 1;310(9):G716-25. doi: 10.1152/ajpgi.00273.2015. Epub 2016 Feb 25. Am J Physiol Gastrointest Liver Physiol. 2016. PMID: 26950855 Free PMC article.
-
Effects of the vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor SU5416 on in vitro cultures of Plasmodium falciparum.Malar J. 2014 May 28;13:201. doi: 10.1186/1475-2875-13-201. Malar J. 2014. PMID: 24885283 Free PMC article.
-
New frontiers in the treatment of multiple myeloma.ScientificWorldJournal. 2006 Dec 6;6:1475-503. doi: 10.1100/tsw.2006.236. ScientificWorldJournal. 2006. PMID: 17160337 Free PMC article. Review.
-
The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation.Am J Pathol. 2004 May;164(5):1531-5. doi: 10.1016/S0002-9440(10)63711-X. Am J Pathol. 2004. PMID: 15111299 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources